日前,2018年度生物技术“猛”公司RAPT Therapeutics(曾名FLX Bio)宣布与韩国的Hanmi Pharmaceutical公司达成数额可高达1.18亿美元的研发合作。Hanmi公司将获得RAPT公司的主打口服癌症免疫疗法FLX475在韩国和中国的研发权益,将在韩国和中国进行FLX475的1/2期临床试验和治疗胃癌患者的2期临床试验,辅助RAPT公司展开的全球性临床...
2020年11月10日,初步试验观察还发现,无论是单药治疗,还是与派姆单抗联合使用,FLX475都显示出良好的安全性。 医学教授、杜克癌症研究所癌症免疫治疗中心主任、RAPT科学咨询委员会成员Scott Antonia博士在新闻发布会上解释道:“FLX475是一种有效的非消耗性CCR4拮抗剂,旨在阻断干扰有效抗肿瘤免疫反应的调节性T细胞。这些...
FLX475 评估FLX475治疗多种癌症适应症的正在进行中的1/2期试验的结果显示,FLX475具有单药治疗活性,与派姆单抗(pembrolizumab,Keytruda)联合使用具有良好疗效,并且生物标志物数据支持其作用机制,该药的开发商RAPT Therapeutics公司宣布。 2020年11月10日,初步试验观察还发现,无论是单药治疗,还是与派姆单抗联合使用,FLX47...
FLX475 (tivumecirnon)在NSCLC 患者中的2期试验的安全性和疗效数据公布。 该试验评估了FLX475,一种口服小分子CCR4拮抗剂,与抑制剂pembrolizumab联合使用。在36例患者可进行疗效评估,其中20例PD-L1阳性。在这...
Tivumecirnon: A CCR4 ANTAGONIST THAT COULD UNLOCK AN IMMUNE RESPONSE AGAINST A BROAD RANGE OF “CHARGED" AND VIRALLY ASSOCIATED TUMORS See how tivumecirnon (FLX475)—designed to block CCR4—may work to potentially treat people with many different types of cancer. Tivumecirnon is currently ...
(Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it will present two posters on FLX475,...
专利名称:一种手性抗肿瘤药物FLX475及其中间体的制备方法 专利类型:发明专利 发明人:梅德盛,杨坤,汪奎,孙高睿,肖程 申请号:CN202010755088.3 申请日:20200731 公开号:CN111732572A 公开日:20201002 专利内容由知识产权出版社提供 摘要:本发明涉及一种手性药物FLX475及其中间体的制备方法,所述方法包括:化合物6...
ChemicalBook provide Chemical industry users with FLX475 Boiling point Melting point,FLX475 Density MSDS Formula Use,If You also need to FLX475 Other information,welcome to contact us.
FLX475 Basic informationMore.. Product Name:FLX475 Synonyms:FLX475 CAS: MF: MW:0 EINECS: Mol File:Mol File Information Error Report Your Email: Browse by NationalityFLX475SuppliersChina suppliers FLX475RecommendSuppliers Recommend You Select Member Companies. ...
“These data further support the antitumor activity for FLX475 with clear demonstration as a monotherapy and encouraging activity in a combination regimen with checkpoint inhibition,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “The...